LAS VEGAS — Claritas Rx has launched Patient Watchtower, a first-of-its-kind care coordination platform designed specifically for patients with specialty and rare diseases. Announced at the ASEMBLIA AXS25 conference, the SaaS-based solution leverages artificial intelligence and machine learning (AI/ML) to identify at-risk patients and ensure they receive timely access to treatments.
The platform provides biopharmaceutical companies with unprecedented visibility into the complex prescription process, helping to coordinate the numerous stakeholders involved in specialty care. By integrating data from case managers, specialty pharmacies, field teams, HUBs, patient support centers, and other care partners, Patient Watchtower delivers real-time insights and suggests the next best action to help patients start and stay on therapy.
“Hyper-targeted coordination within a health enablement and access team (HEAT) can potentially increase fill rates by 20%,” said Mike Fitzgibbons, CEO of Claritas Rx. “For many specialty brands, that level of improvement can translate into millions of dollars and, more importantly, ensure patients receive the treatments they need faster.”
The platform’s core feature set includes a customizable patient journey dashboard, daily updates on high-priority cases, instant access to detailed patient histories, and real-time collaboration tools for care teams. Additionally, predictive analytics assess patient risk factors, such as the likelihood of prescription abandonment or discontinuation, enabling proactive intervention.
Patient Watchtower addresses a critical gap in the specialty pharmaceutical landscape, where complex care pathways and fragmented data often delay treatment. By streamlining communication and decision-making across disparate care teams, the platform helps ensure that life-saving therapies reach patients without unnecessary delays.
Claritas Rx plans to showcase Patient Watchtower’s capabilities in an upcoming webinar, Achieve Specialty Pharma Success with AI: Enhance Care, Elevate Fill Rates by 20% and Improve Patient Adherence, scheduled for May 15.
